Pharma BD Deal Intelligence
Roche acquired Telavant Holdings for $7.1B for gastrointestinal disease drug.
Roche agreed to acquire Telavant Holdings for $7.1 billion upfront and a $150 million near-term milestone payment, gaining rights to RVT-3101 for inflammatory…
Phase III induction study of afimkibart (RO7790121 / RVT-3101) in moderately-to-severely active ulcerative colitis; sponsor Hoffmann-La Roche; start Dec…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche acquired Telavant Holdings from Roivant Sciences in a deal announced October 23, 2023 and completed December 14, 2023, paying $7.1 billion upfront plus a $150 million near-term milestone (up to $7.25 billion). The transaction gave Roche US and Japanese development, manufacturing and commercialization rights to RVT-3101, a novel anti-TL1A (TNFSF15) IgG1 monoclonal antibody for inflammatory bowel disease; Pfizer retained rights outside those territories and Roche also took an option on a next-generation p40/TL1A bispecific. The asset was Phase 3-ready on Phase 2b TUSCANY-2 data showing 36% clinical remission and 50% endoscopic improvement at week 56 in ulcerative colitis. Under Roche the antibody was renamed afimkibart (RG6631 / RO7790121) and advanced to Phase III in ulcerative colitis (Ametrine-2, NCT06588855, initiated December 2024) and Phase II in Crohn's disease and atopic dermatitis, with Roche guiding to a first regulatory filing in UC around 2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Telavant Holdings (this deal) | 2023 | $7.1B | 73 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2023 deals · Roche Holding AG deals · Gastroenterology deals